

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: May 19, 2005

Signature: \_\_\_\_\_

(Harvey L. Cohen)

Docket No.:  
SCHERING 3.0-122  
(PATENT)

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Patent Application of:  
Saksena et al.

Application No.: 09/908,955

Group Art Unit: 1653

Filed: July 19, 2001

Examiner: R. B. Mondesi

For: NOVEL PEPTIDES AS NS3-SERINE  
PROTEASE INHIBITORS OF HEPATITIS C  
VIRUS

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**INFORMATION DISCLOSURE STATEMENT**

Dear Sir:

It is respectfully requested that the references listed on the enclosed form be made of record and considered with respect to the above-referenced U.S. patent application. A copy of each reference is enclosed, as well as a copy of the European Search Report. Submission of the present Information Disclosure Statement should not be taken as an admission that the cited references are legally available prior art or that the same are pertinent or material.

In the event that any fee is due in connection with the present Information Disclosure Statement, the Commissioner is hereby authorized to charge the same to our Deposit Account No. 12-1095.


Dated: May 19, 2005

Respectfully submitted,

By \_\_\_\_\_

Harvey L. Cohen

Registration No.: 28,365  
LERNER, DAVID, LITTENBERG,  
KRUMHOLZ & MENTLIK, LLP  
600 South Avenue West  
Westfield, New Jersey 07090  
(908) 654-5000  
Attorney for Applicant



PTO/SB/08a/b (08-03)

Approved for use through 07/31/2006. OMB 0651-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	09/908,955-Conf. #4478
				Filing Date	July 19, 2001
				First Named Inventor	Anil Saksena
				Art Unit	1653
				Examiner Name	R. B. Mondesi
Sheet	1	of	1	Attorney Docket Number	SCHERING 3.0-122

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)				
	BA	JP-4-001140-A	01-06-1992	Mocrobial Chem		
	BB	GB-2 338 482-A	04-30-1998	Hoffmann La Roche		
	BC	EP-0 195 212-A	09-24-1986	Merrell Dow Pharmaceuticals Inc.		
	BD	WO-97/31937-A	09-04-1997	Akzo Nobel		
	BE	EP-0 363 284-A	04-11-1990	Merrell Dow Pharmaceuticals Inc.		
	BF	WO-96/40743-A	12-19-1996	Cor Therapeutics Inc.		
	BG	JP-04 149166-A	05-22-1992	Nippon Kayaku Co Ltd.		

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	CA	SUTO M.J., et al: "Peptide Inhibitors of IKB Protease: Modification of the C-termini of Z-LLF-CHO", Biorganic & Medicinal Chemistry Letters, Oxford, GB, Vol. 6, No. 24, 12/17/96.	
	CB	PATEL, D.V. et al, "Activated Ketone Based Inhibitors of Human Renin", Journal of Medicinal Chemistry, American Chemical Society, Washington, US, Vol. 36, No. 17, 8/1/93, pages 2431-2447.	
	CC	ASANO et al, "Novel Retrovirus Protease Inhibitors, RPI-856 A, B, C and D, Produced by Streptomyces Sp. AL-322", Journal of Antibiotics, Japan Antibiotics Research Association, Tokyo, JP, Vol. 47, No. 5, 5/1/94, pages 557-565.	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--